Valvular heart disease (VHD) is a common cardiac disease. Patients with severe VHD have a poor prognosis. With the development of minimal invasive treatments in VHD, especially with the wide application of transcatheter aortic valve replacement in aortic stenosis, these diseases have been regained attention. The disease spectrum and modes of treatment have also changed. However, we currently lack a large population-based VHD-related epidemiologic study in China. In this article, we will summarize the current status of VHD in China using available epidemiologic data.
This paper tried to address how to apply the relative concepts and methods of evidence-based medicine in clinical practice of cardiology, especially in diagnosis and treatment, with an aim to promote the cardiovascular evidence-based medicine in China.
Clinical endpoint committee (CEC) plays an important role in the process of the endpoint events adjudication in clinical trials. It greatly influences quality control of clinical trials, the importance of which increases especially after the emergency of the definition of clinical endpoint events by Academic Research Consortium (ARC). In this paper, we briefly introduce the role of CEC in the process of the quality control of clinical trials, application of CEC in China and abroad, and its influence to the primary endpoints. We also investigate the application and development of CEC in the field of cardiovascular diseases, and discuss how to reasonably apply CEC and maximize its role in the process of the endpoint events adjudication of clinical trials.